We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Monkeypox virus (MPXV), a re-emerging member of the Orthopoxvirus genus, has become a significant public health concern due to its increasing global spread and zoonotic potential. As researchers continue to explore effective countermeasures, antibody-based approaches have shown tremendous promise for both therapeutic and diagnostic applications.
At Creative Biolabs, we offer comprehensive antibody development services targeting a curated list of monkeypox viral antigens that are highly conserved, surface-accessible, and functionally essential. These antigens represent the most immunologically relevant hot antibody targets currently available for monkeypox research and product development.
The development of monoclonal antibodies (mAbs) against viral targets requires careful selection of antigens that are:
Focusing on these high-value targets allows for the generation of antibodies with strong binding affinities, potent neutralizing capabilities, and versatile applications in in vitro and in vivo systems.
| Target | Protein Function | Therapeutic/Research Relevance |
|---|---|---|
| A29L | Viral membrane protein involved in morphogenesis | Structural target, useful for virion assembly studies |
| H3L | Envelope protein facilitating viral entry | Induces strong neutralizing antibody responses |
| A33R | Extracellular envelope glycoprotein | Key for intercellular virus spread; immune intervention target |
| D8L | Surface glycoprotein binding host glycosaminoglycans | Validated in protective antibody studies |
| A17L | Core membrane protein for viral assembly | Involved in viral replication and particle integrity |
| B8R | Secreted immune evasion protein (IFN binding) | Immunomodulatory target to restore innate defense |
| E9L | DNA polymerase subunit | Intracellular target for antibody-drug conjugates |
| F13L | Phospholipase essential for extracellular virion formation | Targeted by licensed antivirals; key for viral egress |
| K1L | Host range factor | Supports viral replication in non-native species |
| B5R | Major extracellular virion membrane protein | Vaccine and diagnostic antibody development target |
| VGF | Viral growth factor homolog | Promotes cell proliferation; facilitates viral spread |
Our selected antigen targets encompass early-, intermediate-, and late-stage monkeypox viral proteins, including both structural components and immune-modulating factors involved in viral replication and host-pathogen interactions. This comprehensive coverage across the viral life cycle enables the development of antibodies capable of neutralizing the virus at multiple stages of infection. The table below summarizes the key features of each high-priority target included in our antibody development portfolio:
These proteins represent the most immunogenic and functionally critical components of MPXV, offering valuable entry points for both neutralizing and non-neutralizing antibody development.
Creative Biolabs combines deep expertise in poxvirus immunology with a suite of advanced antibody technologies, including:
Each project is tailored to your scientific goals, whether for preclinical research, diagnostic reagent development, or therapeutic candidate generation. With in-house antigen design, expression, and antibody screening capabilities, we ensure a streamlined workflow and rapid turnaround.
Antibodies generated against these hot monkeypox targets can be applied in:
With over 20 years of experience in antibody discovery and infectious disease research, Creative Biolabs is your ideal partner for monkeypox-related antibody development. Whether you're aiming to create research reagents, diagnostic antibodies, or therapeutic biologics, we are equipped to deliver customized solutions that meet your timelines and scientific standards. Contact us today to learn more or request a quote for our monkeypox hot antibody target services.
We select targets based on surface accessibility, functional importance, immunogenicity, and sequence conservation across monkeypox strains to ensure broad reactivity and therapeutic relevance.
We utilize bacterial, mammalian, and insect cell systems depending on the complexity and post-translational requirements of each protein to ensure proper folding and antigenicity.
Neutralizing antibodies typically target early-stage or surface-expressed proteins to block viral entry, but late-stage targets can be useful in viral spread or immune modulation contexts.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.